norelgestromin profile

norelgestromin: transdermal hormonal contraceptive [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	13752005
MeSH ID	M0417269

Synonym
norelgestromin
15-ethyl-14-ethynyl-5-(hydroxyimino)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-ol
(3z)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Adverse events were typical of hormonal contraception, and most were mild-to-moderate in severity and not treatment limiting."	( Efficacy and safety of a transdermal contraceptive system. Creasy, GW; Fisher, AC; Lenihan, JP; Meador, ML; Shangold, GA; Smallwood, GH, 2001)	0.31
"2%) participants experienced a serious adverse event classified as possibly, probably, or likely related to the patch."	( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002)	0.31
"Overall, the contraceptive patch is well tolerated and has a side effect profile similar to an established oral contraceptive."	( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002)	0.31
"evaluation of the frequency of adverse events during the therapy with a transdermal contraceptive system (TCS) in comparison to an oral contraceptive."	( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Radowicki, S; Skórzewska, K; Szlendak, K, 2005)	0.33
" Safety evaluation was based on the frequency of adverse effects, changes in physical and gynecological examinations."	( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Radowicki, S; Skórzewska, K; Szlendak, K, 2005)	0.33
"The incidence of most adverse effects was similar between the transdermal and oral contraceptive therapies, except of a higher incidence of breast pain, dysmenorrhoea and application site reactions in the patch group."	( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Radowicki, S; Skórzewska, K; Szlendak, K, 2005)	0.33
"The study suggests that a transdermal contraceptive system is a safe and well tolerated therapy."	( [Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Radowicki, S; Skórzewska, K; Szlendak, K, 2005)	0.33

Pharmacokinetics

The study looked at the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra.

Excerpt	Reference	Relevance
"Biotransformation, pharmacologic, and pharmacokinetic studies of norgestimate and its metabolites indicate that 17-deacetyl norgestimate, along with the parent drug, contributes to the biologic response."	( Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Flor, S; Hahn, DW; Kafrissen, ME; McGuire, JL; Phillips, A; Tolman, EL, 1990)	0.28
" This overview summarizes the relevant pharmacokinetic data for the contraceptive patch."	( Pharmacokinetic overview of Ortho Evra/Evra. Abrams, LS; Natarajan, J; Skee, D; Wong, FA, 2002)	0.31
"The contraceptive patch exhibits an excellent pharmacokinetic profile, maintaining efficacious serum hormone concentrations under varying conditions."	( Pharmacokinetic overview of Ortho Evra/Evra. Abrams, LS; Natarajan, J; Skee, D; Wong, FA, 2002)	0.31
"To determine the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra, at each of four anatomic sites (abdomen, buttock, arm, and torso)."	( Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Abrams, LS; Anderson, GD; Natarajan, J; Skee, DM; Wong, FA, 2002)	0.31
" Comparable systemic exposure of EE and 17-DNE in the presence and absence of dexloxiglumide suggests that dexloxiglumide treatment is unlikely to interfere with the safety and efficacy of oral contraceptives based on the analysis of the resulting pharmacokinetic profile."	( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005)	0.33
" The clinical significance of the differences in pharmacokinetic and pharmacodynamic profiles between the patch and oral contraceptive is not fully known."	( Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Devineni, D; Janssens, L; LaGuardia, KD; Leung, AT; Massarella, J; Skee, D; Vaccaro, N, 2007)	0.34
"5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on day 21 of each cycle for determination of AUC0-24 h and Cmax of ethinyl estradiol and norelgestromin."	( Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics. Dunbar, S; Johnson-Levonas, AO; Lasseter, KC; Li, S; Miller, DL; Rosko, K; Schwartz, JI; Wagner, JA; Yuan, J, 2009)	0.35
" The method has been successfully applied to a pharmacokinetic study of the ORTHO EVRA patch in rabbits."	( Determination of norelgestromin in rabbit plasma by LC-MS/MS and its application to the pharmacokinetic study of ORTHO EVRA. Ding, C; Ge, Q; Liu, X; Zhi, X; Zhou, Z, 2009)	0.35

Compound-Compound Interactions

Excerpt	Reference	Relevance
" This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)."	( Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women. Kam, J; Leahy, M; Meka, V; Nestorov, I; Sheikh, SI; Zhao, G; Zhu, B, 2017)	0.46

Bioavailability

Excerpt	Reference	Relevance
" The very poor solubility and wettability of these drugs, along with their high potency (adsorption issues), give rise to difficulties in designing intravenous (IV) formulations to assess absolute bioavailability of products containing both drugs."	( Norelgestromin/ethinyl estradiol intravenous infusion formulation optimization, stability and compatibility testing: A case study to overcome polysorbate 80 interference in chromatographic analysis. Abdallah, IA; Hammell, DC; Hassan, HE; Stinchcomb, AL, 2016)	0.43

Dosage Studied

Norelgestromin and ethinyl estradiol were superimposable following OC alone and OC coadministered with DMF.

Excerpt	Relevance	Reference
" The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 microg/EE 35 microg, significantly decreased mean maximum follicular diameter following a 3-day intentional delayed dosing phase when compared with oral levonorgestrel (LNG) 50/75/125 microg/EE 30/40/30 micorg and oral LNG 100 microg/EE 20 microg, and was as effective as oral LNG 50/75/125 microg/EE 30/40/30 microg and oral desogestrel 150 microg/EE 20 microg in altering cervical mucus composition (i."	( Transdermal contraception. Abrams, LS; Creasy, GW; Fisher, AC, 2001)	0.31
" A major advantage of this method compared to oral contraceptives is a nearly 90% perfect adherence to the dosing schedule across all age groups."	( The transdermal contraceptive patch: a new approach to hormonal contraception. Burkman, RT, )	0.13
"To compare the effects of the contraceptive patch to oral contraceptives (OCs) on follicular size and incidence of ovulation in normal cycles and after dosing errors."	( Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Archer, DF; Creasy, GW; Fisher, AC; Moreau, M; Pierson, RA; Shangold, GA, 2003)	0.32
"Follicular size and incidence of ovulation were significantly reduced among contraceptive patch users compared with women using OCs in normal cycles and after planned dosing errors."	( Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Archer, DF; Creasy, GW; Fisher, AC; Moreau, M; Pierson, RA; Shangold, GA, 2003)	0.32
" Reduced frequency of dosing has the potential to improve patient compliance."	( Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. Henzl, MR; Loomba, PK, 2003)	0.32
"250 mg per 7-day phase, respectively) for 5 days (days 17-21) concurrently with either 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21) or matching placebo during 2 consecutive 28-day OC dosing cycles."	( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005)	0.33

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (1.45)	18.7374
1990's	3 (4.35)	18.2507
2000's	55 (79.71)	29.6817
2010's	10 (14.49)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	29 (39.19%)	5.53%
Reviews	16 (21.62%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (1.35%)	0.25%
Other	28 (37.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial. [NCT01087879]		45 participants (Anticipated)	Interventional	2007-10-31	Completed
An Open Label Multicentre Study to Evaluate Patient Satisfaction and Preference for the EVRA Transdermal Contraceptive System Compared to Previously Used Contraceptive Method. [NCT00653016]	Phase 4	405 participants (Actual)	Interventional	2002-10-31	Completed
A Definitive Bioequivalence Study of ORTHO EVRA Exhibiting Faster Equilibration Profile and Currently Marketed ORTHO EVRA in Healthy Female Volunteers [NCT00775086]	Phase 1	42 participants (Actual)	Interventional	2004-05-31	Completed
Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA [NCT00984789]	Phase 3	393 participants (Actual)	Interventional	2009-05-31	Completed
The Effects of Oral Contraceptive Pills vs Hormonal Patch on Coagulation Parameters [NCT00554632]		24 participants (Actual)	Interventional	2003-04-30	Completed
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon. [NCT00236782]	Phase 3	1,517 participants (Actual)	Interventional	1997-10-31	Completed
An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra [NCT00269620]	Phase 4	500 participants (Actual)	Interventional	2005-06-30	Completed
A Comparative Pharmacokinetic Study of EVRA and CILEST in Healthy Female Volunteers [NCT00254865]	Phase 1	34 participants (Actual)	Interventional	2002-08-31	Completed
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol. [NCT00236769]	Phase 3	1,751 participants (Actual)	Interventional	1997-11-30	Completed
Open-Label, Randomized, Partially Balanced, Incomplete Block Design Study to Evaluate the Hormone Exposure From Commercial EVRA (Manufactured by LOHMANN Therapie-Systeme) and an Oral Contraceptive [NCT00258063]	Phase 1	60 participants (Actual)	Interventional	2004-05-31	Completed
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil. [NCT00236795]	Phase 3	1,494 participants (Actual)	Interventional	1997-01-31	Completed
An Open Label, Multicentre Study of the EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch in Europe: Evaluation of Women's Experience With EVRA� and Comparison With Previously Used Methods of Contraception. [NCT00261482]	Phase 4	778 participants (Actual)	Interventional	2003-07-31	Completed
A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen [NCT00320580]	Phase 2	239 participants (Actual)	Interventional		Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
lynestrenol Lynestrenol: A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.07	1	0	steroid
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	16.05	56	30	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	3.41	1	1	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
17-alpha-hydroxyprogesterone 17alpha-hydroxyprogesterone : A 17alpha-hydroxy steroid that is the 17alpha-hydroxy derivative of progesterone.	2.42	2	0	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin
medroxyprogesterone acetate [no description available]	9.32	3	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
cyproterone acetate [no description available]	2.03	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
medroxyprogesterone [no description available]	3.54	2	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	3.81	2	1	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	3.41	1	1	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	10.19	15	5	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
ethinyl estradiol-norgestrel combination Ethinyl Estradiol-Norgestrel Combination: ETHINYL ESTRADIOL and NORGESTREL given in fixed proportions.	4.9	4	2
desogestrel Desogestrel: A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents (ORAL CONTRACEPTIVES, COMBINED).	8.81	9	3	17beta-hydroxy steroid; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	3.41	1	1	glutamic acid derivative
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	4.34	1	1	iditol	fungal metabolite
testosterone acetate testosterone acetate : An androstanoid that is the acetate derivative of testosterone.	2.02	1	0	3-oxo-Delta(4) steroid; androstanoid; sterol ester	human metabolite
lopinavir [no description available]	4.36	1	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.01	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.36	1	1	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
dimethyl fumarate [no description available]	3.53	1	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator
citraconic acid citraconic acid: was MH 1975-92 (see under MALEATES 1975-90); METHYLMALEIC ACID was see CITRACONIC ACID 1975-92; use MALEATES to search CITRACONIC ACID 1975-92; RN refers to (Z)-isomer; SO refers to (E)-isomer. citraconic acid : A dicarboxylic acid consisting of maleic acid having a methyl substituent at the 2-position.	3.53	1	1	dicarboxylic acid; dicarboxylic fatty acid	human metabolite
bilirubin [no description available]	2.03	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
fondaparinux Fondaparinux: Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.. fondaparinux : A synthetic pentasaccharide which, apart from the O-methyl group at the reducing end of the molecule, consists of monomeric sugar units which are identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate.	2.01	1	0	amino sugar; oligosaccharide sulfate; pentasaccharide derivative	anticoagulant
ethisterone Ethisterone: 17 alpha-Hydroxypregn-4-en-20-yn-3-one. A synthetic steroid hormone with progestational effects.. ethisterone : A 17beta-hydroxy steroid that is testosterone in which the 17beta hydrogen is replaced by an ethynyl group. Ethisterone was the first orally active progestin and is a metabolite of danazol.	15.37	45	19	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	drug metabolite; progestin
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	3.53	1	1	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
etonogestrel [no description available]	7.9	7	2	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
u 62840 U 62840: stereoisomeric benzindene prostaglandin analog; structure given in first source	2.01	1	0	carbotricyclic compound; carboxylic acid	antihypertensive agent; cardiovascular drug; human blood serum metabolite; platelet aggregation inhibitor; vasodilator agent; vitamin K antagonist
tri-cyclen [no description available]	5.07	3	3
n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide: MK-0364 is the (1S,2S)-isomer; a cannabinoid-1 receptor inverse agonist; structure in first source	3.43	1	1	stilbenoid
norgestimate [no description available]	9.25	13	5
c-peptide C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.	2.1	1	0
trelstar Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	2.01	1	0
ortho evra Ortho Evra: a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6 mg norelgestromin and 0.75 mg ethinyl estradiol; was indexed to norelgestromin (2002-2006)	7.05	1	0
dolutegravir [no description available]	3.5	1	1	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
contraceptives, postcoital Contraceptives, Postcoital: Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS.	1.97	1	0
norgestrel Norgestrel: A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.	16.95	76	34
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	2.1	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	4.36	1	1

Condition	Relationship Strength	Studies	Trials
Weight Gain Increase in BODY WEIGHT over existing weight.	5.04	3	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.42	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	13.59	26	21
HIV Coinfection [description not available]	4.36	1	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	4.36	1	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	11.49	18	18
Breast Cancer [description not available]	2.42	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.42	2	0
Emesis [description not available]	2.93	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.34	2	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	2.93	1	0
Acne [description not available]	2.02	1	0
Menstruation, Painful [description not available]	3.82	2	1
Bilateral Headache [description not available]	4.73	2	1
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	2.02	1	0
Dysmenorrhea Painful menstruation.	3.82	2	1
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	4.73	2	1
Drug Withdrawal Symptoms [description not available]	4.32	1	1
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	4.32	1	1
Deep Vein Thrombosis [description not available]	3.35	2	0
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	3.35	2	0
Blood Clot [description not available]	4.34	1	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	4.34	1	1

norelgestromin

Description

Cross-References

Synonyms (3)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (69)

Study Types

Clinical Trials (13)

Trial Overview

norelgestromin

Description

Cross-References

Synonyms (3)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (69)

Study Types

Clinical Trials (13)

Trial Overview

Related Drugs (37)

Related Conditions (23)